Risk of extrapyramidal reactions with aripiprazole

Aripiprazole is a third‐generation antipsychotic with a distinct pharmacological profile. It is a partial agonist at the dopamine D2 receptor, and as such has comparatively fewer D2 receptor‐related adverse effects, such as extrapyramidal reactions. Despite this unique receptor activity, case reports have provided evidence that aripiprazole use could be associated with an increased risk of extrapyramidal reactions, primarily in antipsychotic‐naïve patients.

Source: The Brown University Psychopharmacology Update - December 20, 2016 Category: Psychiatry Authors: Y. W. Francis Lam Tags: Drug ‐Drug Interactions Source Type: research